摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(E)-6-(1,3-dihydro-4,6-dimethoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenohydroxamic acid | 1001329-42-5

中文名称
——
中文别名
——
英文名称
(E)-6-(1,3-dihydro-4,6-dimethoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenohydroxamic acid
英文别名
(E)-6-(4,6-dimethoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-N-hydroxy-4-methylhex-4-enamide
(E)-6-(1,3-dihydro-4,6-dimethoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenohydroxamic acid化学式
CAS
1001329-42-5
化学式
C18H23NO6
mdl
——
分子量
349.384
InChiKey
VEURGGSTVLSJTB-BJMVGYQFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    25
  • 可旋转键数:
    7
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    94.1
  • 氢给体数:
    2
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    (E)-6-(1,3-二氢-4,6-二甲氧基-7-甲基-3-氧代-5-异苯并呋喃基)-4-甲基-4-己烯酸氯甲酸乙酯三乙胺盐酸羟胺盐酸 作用下, 以 四氢呋喃 为溶剂, 反应 10.75h, 以90%的产率得到(E)-6-(1,3-dihydro-4,6-dimethoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenohydroxamic acid
    参考文献:
    名称:
    Hydroxamic Acid Derivatives of Mycophenolic Acid Inhibit Histone Deacetylase at the Cellular Level
    摘要:
    麦克芬酸(MPA,1)是一种IMP脱氢酶(IMPDH)抑制剂和潜在的PPARγ激动剂,作为一种有效的免疫抑制剂用于临床移植,并且最近已在晚期多发性骨髓瘤患者中进入临床试验。另一方面,亚丁酸(SAHA)是一种非特异性组蛋白去乙酰化酶(HDAC)抑制剂,已被批准用于治疗皮肤T细胞淋巴瘤。MPA似乎具有一个帽结构、一个链接器和一个弱金属结合位点,作为HDAC的潜在抑制剂。因此,设计并合成了具有有效金属结合位点的麦克芬酸氢氧酸衍生物:麦克芬酸氢氧酸(MPHA,2)、7-O-乙酰麦克芬酸(7-O-Ac MPHA,3)和7-O-月桂酰麦克芬酸氢氧酸(7-O-L MPHA,4)。所有这些化合物均抑制组蛋白去乙酰化酶,其IC50值分别为1、0.9和0.5μM,细胞增殖抑制浓度为2、1.5和1μM。
    DOI:
    10.1271/bbb.80303
点击查看最新优质反应信息

文献信息

  • Dual Inhibitors of Inosine Monophosphate Dehydrogenase and Histone Deacetylases for Cancer Treatment
    作者:Liqiang Chen、Daniel Wilson、Hiremagalur N. Jayaram、Krzysztof W. Pankiewicz
    DOI:10.1021/jm070864w
    日期:2007.12.27
    Mycophenolic acid (MPA), an inhibitor of IMP-dehydrogenase (IMPDH), is used worldwide in transplantation. Recently, numerous studies showed its importance in cancer treatment. Consequently, MPA entered clinical trials in advanced multiple myeloma patients. Suberoylanilide hydroxamic acid (SAHA), a potent differentiation agent acting through inhibition of histone deacetylases (HDACs), was recently approved for treatment of cutaneous T cell lymphoma. We report herein the synthesis of dual inhibitors of IMPDH and HDACs. We found that mycophenolic hydroxamic acid (9, MAHA) inhibits both IMPDH (K-i = 30 nM) and HDAC (IC50 = 5.0 mu M). A modification of SAHA with groups known to interact with IMPDH afforded a SAHA analogue 14, which inhibits IMPDH (K-i = 1.7 mu M) and HDAC (IC50 = 0.06 mu M). Both MAHA (IC50 = 4.8 mu M) and SAHA analogue 14 (IC50 = 7.7 mu M) were more potent than parent compounds as antiproliferation agents. They were also significantly more potent as differentiation inducers.
  • Hydroxamic Acid Derivatives of Mycophenolic Acid Inhibit Histone Deacetylase at the Cellular Level
    作者:Daniela I. BATOVSKA、Dong Hoon KIM、Shinya MITSUHASHI、Yoon Sun CHO、Ho Jeong KWON、Makoto UBUKATA
    DOI:10.1271/bbb.80303
    日期:2008.10.23
    Mycophenolic acid (MPA, 1), an inhibitor of IMP-dehydrogenase (IMPDH) and a latent PPARγ agonist, is used as an effective immunosuppressant for clinical transplantation and recently entered clinical trials in advanced multiple myeloma patients. On the other hand, suberoylanilide hydroxamic acid (SAHA), a non-specific histone deacetylase (HDAC) inhibitor, has been approved for treating cutaneous T-cell lymphoma. MPA seemed to bear a cap, a linker, and a weak metal-binding site as a latent inhibitor of HDAC. Therefore, the hydroxamic acid derivatives of mycophenolic acid having an effective metal-binding site, mycophenolic hydroxamic acid (MPHA, 2), 7-O-acetyl mycophenolic acid (7-O-Ac MPHA, 3), and 7-O-lauroyl mycophenolic hydroxamic acid (7-O-L MPHA, 4) were designed and synthesized. All these compounds inhibited histone deacetylase with IC50 values of 1, 0.9 and 0.5 μM, and cell proliferation at concentrations of 2, 1.5 and 1 μM, respectively.
    麦克芬酸(MPA,1)是一种IMP脱氢酶(IMPDH)抑制剂和潜在的PPARγ激动剂,作为一种有效的免疫抑制剂用于临床移植,并且最近已在晚期多发性骨髓瘤患者中进入临床试验。另一方面,亚丁酸(SAHA)是一种非特异性组蛋白去乙酰化酶(HDAC)抑制剂,已被批准用于治疗皮肤T细胞淋巴瘤。MPA似乎具有一个帽结构、一个链接器和一个弱金属结合位点,作为HDAC的潜在抑制剂。因此,设计并合成了具有有效金属结合位点的麦克芬酸氢氧酸衍生物:麦克芬酸氢氧酸(MPHA,2)、7-O-乙酰麦克芬酸(7-O-Ac MPHA,3)和7-O-月桂酰麦克芬酸氢氧酸(7-O-L MPHA,4)。所有这些化合物均抑制组蛋白去乙酰化酶,其IC50值分别为1、0.9和0.5μM,细胞增殖抑制浓度为2、1.5和1μM。
查看更多